Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Licenses Polymorphism Patent from Vanderbilt

NEW YORK, Jan. 26 (GenomeWeb News) - Genaissance Pharmaceuticals has exclusively licensed commercial rights to a patent held by Vanderbilt University that it said would expand its ability to provide genetic tests for variants of cardiac ion-channel proteins involved in drug-induced cardiac arrhythmias.

 

Genaissance gained rights to US Patent No. 6,458,542, which covers the screening of patients for susceptibility of drug-induced cardiac arrhythmias by testing for the presence of a common polymorphism in KCNE1, a cardiac ion channel gene. The patent adds to Genaissance's estate of more than 50 issued and pending patents covering five cardiac ion-channel genes associated with Long QT Syndrome.

 

New Haven, Conn.-based Genaissance developed the Familion Test for cardiac channelopathies, including Long QT Syndrome and Brugada Syndrome.

 

Terms of the license were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.